Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Senolytics show promise in combating brain aging and COVID-19 neuropathology

Study reveals that senolytics can reduce aging in human brain organoids and mitigate COVID-19 neuropathology, suggesting their potential as a therapeutic strategy against brain aging and coronavirus-related neurological complications.

15 Nov 2023

Is obesity an independent risk factor for cardiovascular disease?

Researchers explore how obesity contributes to cardiovascular disease by investigating this association in low-risk people.

10 Nov 2023

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Study uncovers link between salt-adding habits and type 2 diabetes

A recent study explored the possible interaction of added salt in food with the rate of new type 2 diabetes mellitus (T2DM) to understand the contribution of long-term sodium intake to diabetes incidence.

2 Nov 2023

In acute myocardial infarction patients, does adding a traditional Chinese medicine compound to standard treatments improve outcomes?

Researchers investigated whether Tongxinluo, a Chinese medicinal compound, could improve clinical outcomes among ST-segment elevation myocardial infarction patients.

26 Oct 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

24 Oct 2023

Community immunity: Steering the evolutionary course of SARS-CoV-2

Researchers in Germany have developed a comprehensive fitness model that forecasts the evolution of SARS-CoV-2 by integrating genetic, epidemiological, and immunological data. The study emphasizes the role of population immunity in shaping viral mutations and provides valuable insights into the emergence of new variants.

24 Oct 2023

Engineered bacteria could offer new treatment for hypertension

Scientists at The University of Toledo have proven that engineered bacteria can lower blood pressure, a finding that opens new doors in the pursuit of harnessing our body's own microbiome to treat hypertension.

24 Oct 2023

Is COVID-19 a risk factor for Alzheimer's disease?

The study explores the interconnected risks between COVID-19 and Alzheimer's Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.

23 Oct 2023

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.

22 Oct 2023

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

20 Oct 2023

Low serotonin levels observed in long COVID and other viral infections

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

20 Oct 2023

Are migraines linked to gut health and chronic non-communicable diseases?

The Links Between Migraines, Gut Health, and Chronic Non-Communicable Diseases (CNCDs).

13 Oct 2023

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

The interplay among chronic kidney disease, metabolic risk factors, and the cardiovascular system.

11 Oct 2023

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

The intricate interactions between gut microbiota and drugs.

11 Oct 2023

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

The efficacy of tea and its catechins in deactivating the Omicron subvariant.

5 Oct 2023

New study reveals BA.2.86 subvariant's surprising dance with antibodies

Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant's sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.

2 Oct 2023

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023